Early phase trial investigating anti-TLR4 DNA aptamer designed to reduce inflammation and myelin loss in ischemic stroke and MS.Primary endpoints—safety and PK. Status: results under confirmation. The gene discussed is TLR4; the disease is ischemic stroke.